Agile Therapeutics Analyst Ratings
Agile Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/30/2022 | 1403.76% | HC Wainwright & Co. | $5 → $3 | Maintains | Buy |
| 07/26/2022 | 401.25% | Maxim Group | → $1 | Upgrades | Hold → Buy |
| 07/11/2022 | 2406.27% | HC Wainwright & Co. | $2.5 → $5 | Maintains | Buy |
| 04/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 11/03/2021 | 1153.13% | HC Wainwright & Co. | $3.5 → $2.5 | Maintains | Buy |
| 09/13/2021 | 1654.39% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 07/27/2021 | 2406.27% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 12/08/2020 | 3408.77% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 03/20/2020 | 2907.52% | HC Wainwright & Co. | $7 → $6 | Reiterates | → Buy |
| 02/18/2020 | 3408.77% | HC Wainwright & Co. | $5 → $7 | Maintains | Buy |
| 02/18/2020 | 3910.03% | RBC Capital | $5 → $8 | Maintains | Outperform |
| 06/07/2019 | 2406.27% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 11/29/2018 | 1403.76% | Maxim Group | → $3 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 12/30/2022 | 1403.76% | HC Wainwright & Co. | 5 美元 → 3 美元 | 维持 | 购买 |
| 07/26/2022 | 401.25% | Maxim 集团 | → 1 美元 | 升级 | 持有 → 买入 |
| 2022 年 11 月 7 日 | 2406.27% | HC Wainwright & Co. | 2.5 美元 → 5 美元 | 维持 | 购买 |
| 04/08/2022 | — | Maxim 集团 | 降级 | 买入 → 持有 | |
| 11/03/2021 | 1153.13% | HC Wainwright & Co. | 3.5 美元 → 2.5 美元 | 维持 | 购买 |
| 09/13/2021 | 1654.39% | HC Wainwright & Co. | 7 美元 → 3.5 美元 | 维持 | 购买 |
| 2021 年 7 月 27 日 | 2406.27% | 加拿大皇家银行资本 | 6 美元 → 5 美元 | 维持 | 跑赢大盘 |
| 12/08/2020 | 3408.77% | HC Wainwright & Co. | 6 美元 → 7 美元 | 维持 | 购买 |
| 03/20/2020 | 2907.52% | HC Wainwright & Co. | 7 美元 → 6 美元 | 重申 | → 购买 |
| 02/18/2020 | 3408.77% | HC Wainwright & Co. | 5 美元 → 7 美元 | 维持 | 购买 |
| 02/18/2020 | 3910.03% | 加拿大皇家银行资本 | 5 美元 → 8 美元 | 维持 | 跑赢大盘 |
| 06/07/2019 | 2406.27% | 奥本海默 | → 5 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 11/29/2018 | 1403.76% | Maxim 集团 | → 3 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Agile Therapeutics (AGRX)?
敏捷疗法（AGRX）的目标价格是多少？
The latest price target for Agile Therapeutics (NASDAQ: AGRX) was reported by HC Wainwright & Co. on December 30, 2022. The analyst firm set a price target for $3.00 expecting AGRX to rise to within 12 months (a possible 1403.76% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年12月30日公布了敏捷疗法（纳斯达克股票代码：AGRX）的最新目标股价。该分析公司将目标股价定为3.00美元，预计AGRX将在12个月内上涨至3.00美元（可能上涨1403.76％）。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Agile Therapeutics (AGRX)?
敏捷疗法（AGRX）的最新分析师评级是多少？
The latest analyst rating for Agile Therapeutics (NASDAQ: AGRX) was provided by HC Wainwright & Co., and Agile Therapeutics maintained their buy rating.
Agile Therapeutics（纳斯达克股票代码：AGRX）的最新分析师评级由HC Wainwright & Co. 提供，Agile Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for Agile Therapeutics (AGRX)?
敏捷疗法（AGRX）的下一个分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Agile Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Agile Therapeutics was filed on December 30, 2022 so you should expect the next rating to be made available sometime around December 30, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Agile Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Agile Therapeutics的最后一次评级是在2022年12月30日提交的，因此您应该预计下一个评级将在2023年12月30日左右公布。
Is the Analyst Rating Agile Therapeutics (AGRX) correct?
分析师对敏捷疗法（AGRX）的评级是否正确？
While ratings are subjective and will change, the latest Agile Therapeutics (AGRX) rating was a maintained with a price target of $5.00 to $3.00. The current price Agile Therapeutics (AGRX) is trading at is $0.20, which is out of the analyst's predicted range.
尽管评级是主观的，并将发生变化，但最新的敏捷疗法（AGRX）评级维持不变，目标股价为5.00美元至3.00美元。Agile Therapeutics（AGRX）目前的交易价格为0.20美元，超出了分析师的预测区间。